Section Arrow
Quote
PLX.NYSE-M
- Protalix BioTherapeutics
Quotes are at least 15-min delayed:2025/07/20 19:13 EDT
Regular Hours
Last
 1.45
-0.05 (-3.33%)
Day High 
1.52 
Prev. Close
1.5 
1-M High
1.67 
Volume 
514.63K 
Bid
1.46
Ask
1.51
Day Low
1.45 
Open
1.51 
1-M Low
1.32 
Market Cap 
119.41M 
Currency USD 
P/E 30.2 
%Yield -- 
10-SMA 1.46 
20-SMA 1.46 
50-SMA 1.61 
52-W High 3.1 
52-W Low 0.8214 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
0.05/0.60
Enterprise Value
123.44M
Balance Sheet
Book Value Per Share
0.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
53.40M
Operating Revenue Per Share
0.80
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed：2025/07/20 19:13 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.